HigherDose Faces Federal and State Regulatory Referrals Over Red Light Therapy Advertising Claims Following NAD Boycott

The wellness and beauty sectors are facing heightened regulatory scrutiny following a decisive enforcement move by the advertising industry’s primary self-regulatory arbiter. The National Advertising Division (NAD), an investigative arm of BBB National Programs, announced on Tuesday that it will refer wellness brand HigherDose to federal and state authorities after the company repeatedly refused to participate in mandatory advertising inquiries. The regulatory referral stems from HigherDose’s marketing claims surrounding two popular at-home wellness products: the Red Light Hat and the Red Light Face Mask.

According to the NAD, the brand declined to engage in two separate self-regulatory inquiries designed to substantiate performance-related advertising claims. As a consequence of this non-participation, the watchdog is escalating the matter outside of the advertising industry’s internal review framework, handing the case over to the Federal Trade Commission (FTC), the Food and Drug Administration (FDA), and relevant State Attorneys General for potential investigation and enforcement action.

The standoff highlights a rare fracture in the typically compliant relationship between commercial brands and advertising watchdogs, illuminating the broader regulatory challenges facing the booming direct-to-consumer wellness tech and light therapy markets.

Anatomy of the Inquiry: Disputed Claims in Light Therapy

The friction between the NAD and HigherDose centers on routine, ongoing monitoring by the self-regulatory body, which routinely audits advertisements across digital platforms, print media, and social channels to ensure claims are substantiated by reliable scientific evidence.

During its systematic sweep of the wellness landscape, the NAD flagged a series of express and implied claims made in HigherDose’s marketing campaigns for its flagship light therapy consumer electronics. Specifically, the NAD questioned promotional assertions regarding the Red Light Hat, which is marketed to consumers as a supportive tool for healthy hair growth. Marketing materials for the device allegedly claimed that the product could actively increase localized blood flow, rejuvenate dormant hair follicles, significantly reduce hair shedding, and physically strengthen hair roots.

Concurrently, the regulatory body turned its attention to the HigherDose Red Light Face Mask. The device, which utilizes low-level light therapy (LLLT) to mimic professional dermatological treatments popularized in clinical settings, was advertised with claims that it could diminish the appearance of fine lines and wrinkles, visibly improve the integrity of the skin barrier, enhance skin firmness, and boost overall skin hydration.

In the advertising industry, therapeutic and physiological claims of this nature require robust, competent, and reliable scientific substantiation—typically derived from randomized, controlled human clinical trials—to prove that the product performs as advertised under normal conditions of use. When the NAD initiates an inquiry, it asks the advertiser to provide this substantiation dossier for independent evaluation by a panel of legal and scientific experts.

HigherDose’s Defiant Stance and the Voluntary Nature of the Process

Rather than submitting its clinical data, internal testing, or scientific literature for review, HigherDose made the calculated decision to boycott the proceedings entirely.

In a formal statement provided to industry media following the announcement, a representative for HigherDose defended the company’s hardware while unapologetically dismissing the regulatory body’s authority. “HigherDose stands behind its Red Light Hat and Red Light Face Mask,” the company representative stated. “NAD’s process is voluntary. After careful consideration, we decided not to take part in this particular process. That decision does not reflect any doubt about our products or our claims, and NAD has made no finding to the contrary.”

This perspective brings to light the fundamental tension underpinning self-regulatory frameworks in modern commerce. The National Advertising Division is not a government agency; it operates as an alternative dispute resolution forum established by the advertising industry in 1971 to police truth in advertising, minimize litigation, and maintain consumer trust without burdening the court system. Because it is non-governmental, participation in its inquiries is technically voluntary.

However, ignoring an NAD inquiry carries severe reputational and legal consequences. When a brand refuses to cooperate, the NAD exercises its ultimate punitive mechanism: publicly closing the inquiry and referring the file directly to government regulators who possess statutory authority to issue subpoenas, levy multi-million-dollar fines, and initiate federal lawsuits.

A Statistical Rarity in Industry Compliance

To understand the gravity of HigherDose’s decision, one must examine the compliance metrics governing the self-regulatory system. Referrals to government agencies are statistically uncommon, as the overwhelming majority of commercial brands view cooperation with the NAD as a standard cost of doing business and a safer alternative to public regulatory battles.

“We identified two specific products with pretty strong performance claims, and the advertiser did not want to participate in the self-regulatory process,” explained Annie M. Ugurlayan, assistant director of the National Advertising Division at BBB National Programs, during an interview discussing the case.

Ugurlayan emphasized how unusual HigherDose’s stonewalling is within the broader context of consumer protection enforcement. “Referrals are very rare. Most companies do participate,” she noted. “We have an over 90 percent compliance rate, so it is really a handful of cases that we have every year where they do result in referrals.”

By stepping outside of the 90 percent compliance majority, HigherDose has transitioned from managing a standard peer-review advertising dispute to facing potential crosshairs from state and federal law enforcement agencies.

The Escalation Pathway: FTC, FDA, and State Attorneys General

With the case now formally referred, the ball is in the court of government regulators. The involvement of multiple enforcement bodies introduces substantial legal and financial exposure for the wellness brand.

The Federal Trade Commission serves as the primary federal consumer protection agency, wielding broad jurisdiction under Section 5 of the FTC Act to prohibit unfair or deceptive acts or practices. In the context of health, wellness, and beauty products, the FTC maintains rigorous standards. Under its guidance documents, any product claiming to treat, cure, mitigate, or prevent a medical condition—or purporting to alter the structure or function of the human body (such as promoting hair growth or reversing skin aging)—must be backed by competent and reliable scientific evidence prior to marketing. If the FTC investigates HigherDose and finds the company’s evidentiary backing insufficient, it can pursue civil penalties, force consumer refunds, or impose stringent consent decrees restricting future marketing language.

Concurrently, the Food and Drug Administration holds regulatory authority over devices that diagnose, cure, mitigate, treat, or prevent disease, or affect the structure or function of the body. While many consumer-grade light therapy masks and caps are marketed as general wellness or cosmetic devices, the boundary between cosmetic enhancement and medical device regulation can quickly blur when specific physiological claims—such as follicle rejuvenation or barrier repair—are introduced into promotional copy.

Finally, the inclusion of State Attorneys General in the referral opens the door for coordinated multi-state investigations or individual state-level enforcement actions under state consumer protection statutes (often referred to as "Little FTC Acts"). State AGs have increasingly stepped into the national regulatory vacuum to police misleading wellness and beauty marketing, utilizing civil investigative demands to probe corporate substantiation files.

Broader Industry Implications: The Booming Wellness Tech Wild West

The HigherDose referral does not occur in a vacuum. It reflects a much broader, systemic regulatory reckoning within the multi-billion-dollar wellness technology and at-home beauty device industry.

Over the past half-decade, consumer demand for clinical-grade treatments translated into portable home formats has skyrocketed. Driven by social media marketing, influencer endorsements, and pandemic-era shifts toward at-home self-care, the market has been flooded with LED face masks, infrared blankets, red light caps, microcurrent wands, and radiofrequency devices. Many of these products command premium price points ranging from hundreds to thousands of dollars, often backed by sleek branding and alluring marketing promises.

However, the scientific rigor underpinning many of these products has occasionally lagged behind aggressive marketing copy. While photobiomodulation (low-level light therapy) is supported by legitimate dermatological and trichological research in clinical settings, translating those clinical results to consumer-grade hardware with specific power outputs, wavelengths, and user compliance levels remains scientifically complex.

Recognizing this vulnerability, regulatory watchdogs and competing brands have ramped up scrutiny. The NAD has increasingly cast its analytical eye over the wellness sector, scrutinizing everything from ingestible supplements and functional beverages to sophisticated hardware devices.

The regulatory landscape is further complicated by competitor-driven enforcement. Self-regulatory challenges are frequently initiated not just by the NAD’s internal monitoring initiatives, but by formal challenges filed by rival corporations seeking a level playing field. For instance, the fierce competitive dynamics within the beauty and wellness market frequently lead to cross-brand scrutiny. A notable precedent occurred last year when Huda Beauty voluntarily agreed to modify or drop advertising claims surrounding its Easy Bake Setting Spray following an expedited challenge by rival prestige brand Charlotte Tilbury Beauty—a dispute that was fast-tracked through the NAD framework.

Unlike Huda Beauty, which opted for voluntary compliance and adjustment of its marketing assets, HigherDose has chosen a confrontational pathway of non-engagement. This strategy shifts the battlefield from a private forum of advertising experts to the public and potentially litigious arena of federal oversight.

What Lies Ahead for HigherDose

As the referral letters make their way to Washington, D.C., and state capital offices, HigherDose faces a period of operational uncertainty. It remains entirely at the discretion of the FTC, the FDA, and the targeted State Attorneys General whether to formally open investigations into the brand’s substantiation files. Government agencies operate under strict resource constraints and prioritize cases based on consumer harm, market prevalence, and the egregiousness of the alleged deception. Given the high visibility of the light therapy market and the explicit nature of HigherDose’s hair growth and skin-rejuvenation claims, regulatory interest is far from guaranteed to be dismissive.

For consumers, the public rupture between HigherDose and the advertising watchdog serves as a stark reminder of the limitations of self-regulation in the modern direct-to-consumer economy. As wellness technology continues to merge with personal care, the burden falls increasingly on regulatory authorities to draw the line between substantiated science and marketing hyperbole. Whether HigherDose’s defiant gamble pays off or triggers a costly federal reckoning will depend entirely on the strength of the scientific dossier the company was unwilling to share with the industry’s independent arbiters.